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ABSTRACT 
Objective:  Traumatic brain injury (TBI) is the number one cause of death under 44 years of age; in spite of 
this fact, there is no standard available pharmacological agent for the treatment of brain injury. We 
evaluated the effectiveness of magnesium sulfate treatment for the management and outcome of TBI. 
Material and Methods:  The prospective cases (n = 60) of TBI were included with non-probability 
consecutive sampling. They received standard protocol treatment for TBI and magnesium sulfate as an add 
on therapy. GCS was noted on two occasions, at the time of admission and on the 3rd day. T-test was used 
to compare the results and for identification of significance/insignificance results. 
Results:  Mean age of the patients was 37.12 ± 13.25 years. Majority were male (68.3%), while females were 
31.7%. Mean duration of an elapsed post traumatic brain injury was 5.06 ± 2.32 hours. Mean GCS before 
magnesium sulfate treatment (on admission) was 5.46 ± 1.521; mean Glasgow coma (GCS) after magnesium 
sulfate treatment (on 3rd day) was 8.03 ± 2.56. There existed a significant difference between the GCS scores 
at the time of admission and on 3rd day (p value < 0.0001). Mean GCS was 7.69 ± 2.55 in age < 30 years and 
it was 8.29 ± 2.57 in age > 30 years, but this difference was not statistically significant. Similarly, the 
difference was not significant in the GCS with respect to gender and duration of disease. 
Conclusion:  A significant improvement was found in the GCS after magnesium sulfate therapy in patients 
with TBI. 
Keywords:  Glasgow Outcome Score (GCS), Traumatic Brain Injury (TBI), Magnesium Sulfate. 
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INTRODUCTION 
An outside force to the head cause CNS damage 
occurs in the form of traumatic brain injury (TBI) 
and its dysfunction. Different scales are used to 
quantify the head injury; the most common 
among them is the Glasgow Coma Scale (GCS) 
score.1 Injury to the brain is one of the major 
cause of deaths and morbidity across the world; 
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especially among the individuals whose age is 
below 44 years. Head injury can cause memory 
loss, weakness of limbs, unconsciousness, coma 
and death. The most commonly affected age 
group is between 27 to 60 years.2 
 The leading cause of head injury is motor 
vehicle related accidents, fall from height and 
work related injuries.3 Despite of all these facts 
and data, there is no recommended, standard 
pharmacological agent as a therapy for TBI. 
Medical management is the requirement for 
prevention of secondary brain injury.4 During the 
initial phase of TBI the excitotoxic events in the 
brain results in neuronal cell death.5 Various 
researches have been done but still no effective 
treatment is available to stop this cycle of 
excitotoxicity which leads to cell death.6 
 Various researches have shown the 
neuroprotective agent for the CNS.7In one study, 
there was significant improvement in GCS after 
magnesium sulfate therapy.7 In another research, 
the head injury patients received magnesium 
sulfate bolus dose of fifty mg/kg body weight 
after that every six hourly patients were given fifty 
mg/kg MgSO4 for twenty four hours. The effects 
of the treatment were assessed with Glasgow 
Coma Scale (GCS) score and motor function 
scores which were followed till two months post 
treatment. There was obvious significant 
improvement in the GCS score after two months 
(statistically significant p = 0.03). Data from many 
studies have shown that after severe brain injury 
the free magnesium levels in the brain fall around 
fifty percent in the initial hours. Outcome of the 
patients improved when magnesium levels were 
brought upto the normal baseline levels with the 
use of various pharmacological approaches.8-9 
 One study (randomized control trial) showed 
improvement in GCS (on the third day) and GOS 
with magnesium sulfate therapy as compared to 
the control group in which only standard 
treatment was given without magnesium. Data 
from recent meta-analysis of existing randomized 
controlled trials show that magnesium sulfate has
a role in improving the GCS and GOS scores.8-9-10 
 Mechanism of magnesium has been studied 
in different animal researches; it has a neuro 
protective action by blocking the NMDA and 
calcium channel receptors along with that it 
inhibits the excitatory neurotransmitter release.12-
14 The purpose of the study was to determine 
mean GCS in patients with head injury after 
magnesium sulfate therapy. Also to see the short 
and long term effects of magnesium on the 
outcome of patients. This study can add useful 
data which can be utilized for the betterment of 
the patients. Results were compared with 
international studies available. 
 
MATERIALS AND METHODS 
Study Setting and Sampling 
A prospective case series study was conducted in 
the Department of Neurosurgery at Shaikh Zayed 
Hospital (SZH), Lahore from May 2018 to July 
2019.We enrolled 60 patients who presented with 
traumatic brain injury (TBI). Written Informed 
consents were taken from all patients or from the 
attendantsas per institutional ethical standards. 
 Patients were selected on the basis of non-
probability consecutive sampling. Patients 
background information and clinical 
presentations were recorded. Patients were 
evaluated consisting of a detailed history, physical 
examination (history of loss of consciousness, ENT 
bleed, fits, vomiting, anterograde and retrograde 
amnesia). 
 
Inclusion Criteria 
We included patients of both genders with 
traumatic brain injury with age between 18 – 70 
years who gave consent. 
 
Exclusion Criteria 
We excluded pregnant women, children less than 
18 years of age, patients with poly trauma, 
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patients with significant metabolic diseases 
(chronic kidney disease, ischemic heart disease, 
cardiac failure) and those patients who did not 
give consent. 
 
Clinical Information 
All patients had undergone a CT scan (brain 
plain). Baseline investigations, including complete 
blood count, coagulation profile, LFTs, RFTs and 
other relevant investigations were done as 
preoperative workup. TBI patients were given 
standard treatment (patient were managed 
according to brain trauma guidelines, 
nasogastric/Foleys passed, intravenous fluids, 
Mannitol infusion, antibiotics, nutrition, 
antiepileptic as required, surgery if indicated) plus 
magnesium sulfate. 
 
Treatments of TBI 
The regular mode of treatment for TBI was that 
they received standard protocol treatment 
(patient is managed according to brain trauma 
guidelines, NG/Foleys passed, intravenous fluids, 
Mannitol infusion, antibiotics, nutrition, 
antiepileptic as required, surgery if indicated) and 
along with this patients were given magnesium 
sulfate as an add on therapy. Treatment 
guidelines consisted of an initial loading dose of 
50 mg/kg magnesium sulfate and then 15 mg/kg 
T.D.S up to 48 hours after the trauma. GCS score 
and serum magnesium levels were noted on two 
occasions, at the time of admission and on the 
3rd day. 
 
Data Analysis 
Data analysis was performed in SPSS (v.22.0, IBM 
Corporation) software. All the variables, 
includingsocial, demographic data like name, age, 
sex and address was collected. The clinical 
outcome was evaluated by using GCS (on 
admission and at 3rd day). Categorical variables 
like gender was described as frequencies and 
percentages. Quantitative variables like age, 
weight, height, was described as mean +/- 
standard deviation. The continuous variable like 
serum Magnesium levels and age was presented 
in the form of mean and S.D. Qualitative variable 
like gender and grades of Glasgow Coma Scale, 
was presented in the form of frequency and 
percentages. Data was stratified by age and 
gender with regard to outcome variable, i.e. 
Glasgow coma scale score. T test was used to 
compare the results and for identification of 
significance/insignificance results. A p value 
≤ 0.05 was considered as significant. 
 
Table 1: Mean Glasgow Coma Score before and after magnesium 
sulfate treatment. 
 Condition Mean ± SD p Value 
Glasgow 
coma scale 
(GCS) 
Before Magnesium sulfate 
treatment (on admission) 
5.46 ± 
1.521 
0.0001 (highly 
significant) 
T test: 6.7213; 
df: 118 
After Magnesium sulfate 
treatment (on 3rd day) 
8.03 ± 2.56 
 
Table 2: Glasgow Coma score with respect to age. 
 Age Category Mean ± SD p-value 
  Glasgow Coma 
  Score 
18 – 30 years 7.69 ± 2.55 
0.37 
> 30 years 8.29 ± 2.57 
 
RESULTS 
Age Incidence 
The mean age of the study 
participants was 37.12 ± 13.25 years. 
 
Gender Distribution 
Main component of the patients were 
male 41 (68.3%) while few were 
female 19 (31.7%). 
 The mean duration of an elapsed 
post traumatic brain injury was 5.06 ± 
2.32 hours. 
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Compassions of Glasgow Coma 
Score (GCS) 
Mean GCS before magnesium sulfate 
treatment (on admission) was 5. 46 ± 1. 
521; mean Glasgow coma (GCS) after 
magnesium sulfate treatment (on the 
3rd day) was 8.03 ± 2.56. There existed a 
significant difference between the GCS 
scores at the time of admission and on 
the 3rd day (p value < 0.0001) (Table 1). 
In this study, it is noted that the mean 
Glasgow coma score was 7. 69 ± 2. 55 at 
age < 30 years and it was 8.29 ± 2.57 in 
age group > 30 years, but the difference 
 
Table 3: Glasgow Coma score with respect to gender. 
 
Gender of 
Patients 
Mean± SD p-value 
  Glasgow Coma  
  Score 
Male 8.1220 ± 2.58065 
0.69 
 Female 7.8421 ± 2.58764 
 
Table 4: Glasgow Coma score with respect to duration of 
disease. 
 Duration of Disease Mean± SD p-value 
Glasgow Coma 
Score 
1 – 6 hours 8.1220 ± 2.57094 
0.69 
> 6 hours 7.8421 ± 2.60903 
 
was not statistically significant (Table 2). Similarly, 
there was no significant difference in the Glasgow 
coma score with respect to gender and duration 
of disease (Tables 3-4). 
 
DISCUSSION 
This research provides a data on the effectiveness 
of magnesium sulfate treatment in the patients 
with traumatic head injury. In this study, both GCS 
scores before magnesium sulfate treatment (on 
admission) and after magnesium sulfate 
treatment (on the 3rd day) were compared. 
Results clearly show a significant improvement in 
the GCS after magnesium sulfate treatment. There 
is a need to do human trials to see the 
effectiveness and safety profile of magnesium 
levels in the CSF.15 One randomized controlled 
trial provided a data on the effectiveness of five 
days magnesium therapy by assessing the GCS 
and GOS scores in patients. They compared the 
results with a control group, which received only 
standard therapy for traumatic brain injury 
without magnesium sulfate.16 
 In a study, it was found that the I/V infusion of 
magnesium sulfate only slightly increases the 
levels in CSF.17 
 We need to find out whether this minimal 
increase in magnesium sulfate levels will raise the 
cellular concentration of free magnesium which is 
neuro-protective.18 Levels of magnesium in CNS 
depend on the integrity of the blood brain 
barrier.Trauma in animals damages the blood 
brain barrier which results in increase magnesium 
concentration in the cell for twenty four hours, 
this doesn’t happen in human CNS.19 
 Neuronal cell death after brain injury has 
multiple factors that are why combination therapy 
is recommended in many reports. Combination 
therapies target more than one factor, and they 
have gained attention over the period of time and 
have more efficacy. Various combination 
therapies have been studied in patients with brain 
injury like magnesium in combination with 
growth factors, glutamate antagonists, vitamin B, 
immunosuppressant, hypothermia, antioxidants. 
Combination therapy of magnesium and 
hypothermia gave better results on the outcome 
of head injury patients. More studies need to be 
done to see the effectiveness of combination 
therapy of magnesium and hypothermia. 20This 
research showed that magnesium sulfate 
improves the GCS score of brain injury patients 
and ultimately the outcome. Further studies need 
to done to generalize the results so that patients 
can benefit from the add on therapy of 
magnesium sulfate. 
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CONCLUSION 
A significant improvement was noted in GCS after 
magnesium sulfate therapy in patients with TBI. 
Itis recommended for abetter outcome of 
patients with TBI. However, more studies need to 
be done for the generalizability of the results. 
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